编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
---|---|---|---|---|
20522 | (S)-5-fluoro-3-methylbenzo[c][1,2]oxaborol-1(3H)-ol | 2921961-53-5 | 98% Min. | |
20523 | 1-乙基-1H-吡唑-4-甲醛 | 304903-10-4 | 98% Min. | |
20543 | (1S,5S)-1-(羟甲基)-3-氮杂双环[3.1.0]己烷-3-羧酸叔丁酯 | 1932534-25-2 | 98% Min. | |
20576 | STX-721 | 2765525-82-2 | ≧98.0% | |
STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
20618 | Pirtobrutinib | 2101700-15-4 | 98% Min. | |
20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | |
QN-302 是一种 G4选择性转录抑制剂。 | ||||
20640 | AAG-1 ( FLAG-003 ) | 1614235-14-1 | ≧98.0% | |
FLAG-003 是一种多效水溶性小分子治疗药物,旨在通过两种成熟的作 | ||||
20641 | KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) | 2082765-42-0 | ≧98.0% | |
KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) 是一种蛋白质精氨酸脱亚胺酶的 | ||||
20642 | OATD-02 | 2146132-73-0 | ≧98.0% | |
OATD-02 是一种口服双精氨酸酶抑制剂(ARG1 和 ARG2),目前在 Molecu | ||||
20650 | Sonrotoclax (BGB-11417) | 2383086-06-2 | ≧98.0% | |
Sonrotoclax is an antineoplastic. | ||||
262401 | MRTX1719 | 2630904-45-7 | ≧96.0% | |
MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively | ||||
24002 | 6,11-二氧代-6,11-二氢-5H-苯并[b]咔唑-2-甲酸叔丁酯 | 3024657-88-0 | ≧96.0% | |
Tert-butyl 6,11-dioxo-6,11-dihydro-5H-benzo[b]carbazole-2-carboxylate, CAS 3024657-88 |